medigraphic.com
ISSN 0210-5187 (Electronic)

2007, Number 6

<< Back Next >>

Med Cutan Iber Lat Am 2007; 35 (6)

Photodynamic therapy

Moreno AGA, Eng LA, Alvarado DA, Camps-Fresneda A

Language: Spanish
References: 104
Page: 255-268
PDF size: 251.19 Kb.


ABSTRACT

Photodynamic therapy is based in the interaction of a photoactive agent that when is properly stimulated by a specific wavelength it induces free radicals that lead to cellular necrosis. This is one of the newest treatments for some types of cancer and other inflammatory diseases. In dermatology, photodynamic therapy is used for malignant neoplasias such as basal cell carcinoma, Bowen disease —in situ squamous cell carcinoma— and more recently it has been applied to inflammatory skin diseases such as acne, rosacea, lichen plannus, lichen sclerosus et atrophicus, and other conditions— leishmaniasis, photodamaged skin, telagiectasias1.


REFERENCES

  1. Morton CA, Brown SB. Guidelines for topicalphotodynamic therapy: report of a workshop of the British Photodermatology group. Br JDermatol2002;146:552-67.

  2. Daniell MD, Hills JS. A history of photodyna-mic therapy. Aust NZ Surg 1991;61:340-8.

  3. Lipson RL, Gray MJ Baldes EJ. Hemato-porphyring derivate for detection and management of cancer. En: Proceeding 9th Inter-national Cancer Congress, Tokio, Japan1966; 393.

  4. Figgie FH. Weiland GS Manganiello LO. Can-cer detection and therapy. Affinity of neoplastic, embryonic and traumatic tissue forporphyrins and metallo-porphyrins. ProcSoc Exp Biol Med 1948;68:640-1.

  5. Brown SG, Rogowska AZ, Whitelaw DE. Pho-todynamic therapy for cancer of pancreas. Gut 2002;50:549-57.

  6. Ibboston SH. Topical 5 aminolevulenic andphotodynamic therapy for the treatment of skin conditions other than no melanomaskin cancer. Br J Dermatol2002:146:178-88.

  7. Hopper C. Photodynamic therapy: a clinicalreality in the treatment of cancer. Lancet Oncol 2000;1:212-9.

  8. Babilas P, Landthaler M. Szeimies RM. Pho-todynamic therapy in dermatology. Eur J Dermatol 2006;16:340-8.

  9. CappugiP, CampolmiP, MaviliaL,PrignanoF, RossiR. Topical 5-aminolevuli-nic acid and photo dynamic therapy in der-matology: a minireview. J Chemother2001;13:494-502.

  10. Braathen L, Paredes B, Saksela. An openexplanatory (fase I-II) study of Metvix cream 80 mg- gram and 160 m mg-gr in patientswith primary actinic queratoses. J Eur Acad Dermatol Venereol 2000;14:38.

  11. Ibbotson SH, Jong C, Lesar A. Characteris-tics of 5-aminolaevulinic acid-induced protoporphyrin IX fluorescence in human skinin vivo. Photodermatol Photoinmunol Photomed 2006;22:105-10.

  12. Siddiqui MA, Perry CM, Scott LJ. Topicalmethyl aminolevulinate. Am J Clin Dermatol 2004;5:127-37.

  13. Marti A, Jichlinski P, Lange N, Ballini JP.Comparison of aminolevulinic acid and hexylester aminolevulinate induced proto-porphyrin IX distribution in human bladder cancer. J Urol 2003;170:428-32.

  14. Juzeniene A, Juzena P, Ma LW. Topical appli-cation of 5-aminolaevulinic acid, methyl 5-aminolevulinate and hexil 5-aminolaevulina-te on normal human skin. Br J Dermatol 2006;155:791-9.

  15. Gold MH. Aminolevulinic acid photodyna-mic therapy: medical evidence for its expanded use. Expert Rev Med Devices 2006;3:357-71.

  16. Cunliffe WJ. Goulden V. Phototherapy andacne vulgaris. Br J Dermatol 2000;142:853-6.

  17. Santos MA, Belo VG, Santos G. Effectivenesof photodynamic therapy with topical 5 aminolevulinic acid and intense pulsed Lightversusintense pulse Light alone in the treatment of acne vulgaris: comparative estudy.Dermatol Surg2005;31:910-5.

  18. Taub AF. Photodynamic therapy for the treat-ment of acne: a pilot study. J Drugs Dermatol 2004;3:s10-14, 42.

  19. Kimura M, Itoh Y, ToKuoka Y. Delta-aminole-vulinic acid-based photodynamic therapy for acne on the body. J Dermatol 2004;31:956-60.

  20. Hongcharu W, Taylor CR, Chang Y. TopicalALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol2000;115:183-92.

  21. Alexiades-Armenakas M. Long-Pulsed dyelaser-mediated photodynamic therapy combined with topical therapy for mild to severe comedonal, inflammatory, or cystic acne. JDrugs Dermatol 2006;5:45-55.

  22. Borrelli C, Merk K, Plewig G. Light, laser andTFD therapy for acne. Clin Exp Dermatol 2005;30:723-4.

  23. Gold MH, Bradshaw VL. The use of a novelintense pulsed light and heat source and ALA-PDT in the treatment of moderate tosevere inflammatory acne vulgaris. J Drugs Dermatol2004;3: s15-9.

  24. Wiegell SR, Wulf HC. Photodynamic therapyof acne vulgaris using 5 aminolevulinic acid versus methyl aminolevulinate. J Am AcadDermatol2006;54:647-51.

  25. Katz B, Patel V.Photodynamic therapy for thetreatment of erythema, papules, and severe flushing consistent with rosacea. J DrugsDermatol 2006;5:6-8.

  26. Nybaek H, Jemec G. Photodynamic therapyin treatment in rosacea. Dermatology 2005:211:135-8.

  27. Kuijpers DI, Thissen MR, Thissen CA. Simi-lar effectiveness of methyl amonolevulinate and 5-aminolevulinate in topical photodyna-mic therapy for nodular basal cell carcinoma. J Drugs Dermatol2006;5:642-5.28.Rhodes LE, de Rie M, Enstrom Y. Photodynamic therapy using topical methylaminole-vulinate vs. surgery for nodular basal cellcarcinoma: results of a multicenter randomi-zad prospective trial. Arch Dermatol 2004;140:17-23.

  28. Angell-Petersen E, Sorensen R, Warloe T.Porphyrin formation in actinic keratosis and basal cell carcinoma after topical applicationof methyl 5-aminolevulinate.J Invest Dermatol2006;126:265-71.

  29. Soler A. A follow-up study of recurrence andcosmesis in completely responding superficial and nodular basal cell carcinomas trea-ted with methyl 5 aminolevulinate-based photodynamic therapy alone and with priorcurettage. Br J Dermatol2001;145:467-71.

  30. Morton C. Photodynamic therapy for non-melanoma skin cancer and more. Arch Dermatol 2004;140:116-20.

  31. Horn M. Topical methyl aminolevulinatephotodynamic therapy in patients with basal cell carcinoma prone to complications andpoor cosmetic outcome with conventionaltreatment. Br J Dermatol 2003;149:1242-9.

  32. Marmur ES, Schmults CD, Goldberg DJ. Areview of laser and photodynamic therapyfor the treatment of non melanoma skin can-cer. Dermatol Surg 2004;30:264-71.

  33. Fink-Puches R, Sover HP. Long term follow-up and hitological changes of superficial non melanoma skin cancers treated withtopical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol 1998;134:821-6.

  34. Siddiqui MA, Perry CM. Topical methyl ami-nolevulinate. Am J Clin Dermatol 2004;5:127-32.

  35. Oseroff E. Treatment of diffuse basal cell car-cinoma and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome bywide-area 5 aminolevulinic acid photodynamic therapy. Arch Dermatol 2005:141:60-7.

  36. A Morton M. Photodynamic therapy for largeor múltiple parches of Bowen disease andbasal cell carcinoma. Arch Dermatol 2001;137:393-5.

  37. Salim A, Leman JA, McColl JH. Randomizedcomparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. BrJ Dermatol2003;148:539-43.

  38. Morton C, Horn M, Leman J. Comparison oftopical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracilfor treatment of squamous cell carcinoma in situ: Results of a multicenter randomizedtrial. Arch Dermatol 2006;142:729-35.

  39. Morton CA, Whitehurst C, Moore JV. Comparison of red and green light in the treatment of Bowen´s disease by photodynamic the-rapy. Br J Dermatol2000;143:767-72.

  40. Usmani N, Stables GI. Subungual Bowen’sdisease treated by topical amino levulinicacid-photodynamic therapy. J Am Acad Der-matol2005;53:S273-6.

  41. Britton JE, Goulden V, Stables G. Investiga-tions of use pulses dye laser in the treatment of Bowen’s disease using 5-aminolaevulinicacid phototherapy. Br J Dermatol 2005;153:780-4.

  42. Aisch T, Szeimis R, Jori G. antibacterial pho-todynamic therapy in dermatology. Photochem Photobiol Sci2004;3:916-7.

  43. Embleton M, Nair S, Heiwood W. Develop-ment of a novel targeting system for letal photosensitization of antibiotic-resistand strains of staphyloccocus aureus. Antimicrob agents Chemother2005:49:3690-6.

  44. Hamblin MR, Hasan T. Phodynamic the-rapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci2004;3:5: 436-50.

  45. Cohen PR, Schulze KE, Tshen JA. Treatmentof extramammary Paget disease with topicalimiquimod cream: case report and literaturereview. South Med J2006;99:396-402.

  46. Wilinson EJ, Brown HM. Vulvar Paget disea-se of urothelial origin: a report of three cases and a proposed classification of vulvar Pagetdisease. Hum Pathol 2002;33:549-54.

  47. Raspagliesi F, Fontanelli R, Rossi G. Pho-todynamic therapy using a methyl ester of 5-aminole vulinic acid in recurrent Paget’sdisease of the vulva: A pilot study. Gynecol Oncol 2006;103:581-6.

  48. Xu S, Wang X, Xu Y. Evaluation of photodyna-mic therapy of skin cancers with partial differential alpha-aminolevulinic acid. Chin MedJ (Engl)2002;115:1141-5.

  49. Karrer S, Bosserhoff AK, Weiderer P. Influen-ce of 5 aminolevulínic acid and red light oncollagen metabolism of human dermal fibro-blasts. J Invest Dermatol 2003;120:325-31.

  50. Karrer S, Bosserhoff AK, Waiderer P. Kerati-nocyte-derived cytokines after photodynamic therapy and their paracrine induction ofmatrix metalloproteinases in fibroblasts. Br J Dermatol 2004;15:776-83.

  51. Sunderkotter C, Kuhn A, Hunzelmann N.Phototherapy: a promising treatment optionfor skin sclerosis in scleroderma? Rheumatology (Oxford) 2006;45:iii54.

  52. Holck DE, Ng JD. Facial skin rejuvenation.Curr Opin Ophthalmol 2003;14:246-52.

  53. Alam M, DesJardin J, Arndt KA. A qualityrating scale for aesthetic surgical procedures. J Am Acad Dermatol 2006;54:272-81.

  54. Touma D, Gilchrest B. Topical photodynamic therapy: a new tool in cosmetic dermatology. Sem Cut Med Surg 2003;22:124-30.

  55. Ruiz-Rodríguez R, Sanz-Sánchez T, Córdoba S. Photodynamic photorejuvenation. Dermatol Surg2002;28:742-4.

  56. Alam M, Dover JS. Treatment of Photoaging with topical aminolevulínico acid andlight. Skin therapy Lett 2004 Dec-2005Jan;9:7-9.

  57. Dover JS, Bhatia AC, Stewart B. Topical 5 aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch Dermatol 2005;141:1247-52.

  58. Kvacheva Z, Lobanok E, Votiakov V. Pho-todynamic inhibition of infection caused by herpes simplex virus tipe I in the culturedcells, by using 5 aminolevulinic acid-induced porphyrins. Vopr Visusol 2005;50:44-7.

  59. Alster TS, Tanzi EL. Photodynamic therapywith topical aminolevulinic acid and pulseddye laser irradiation for sebaceous hyperpla-sia. J Drugs Dermatol2003;2:501-4.

  60. Touma DJ, Gilchrest BA. Topical photodynamic therapy: a new tool in cosmetic dermato-logy. Semin Cutan Med Sug2003;22:124-30.

  61. Gardlo K, Horska Z, Enk CD. Treatment of cutaneous leishmaniasis by photodynamictherapy. J Am Acad Dermatol 2003;48:893-6.

  62. Asilian A, Davami M. Comparison between the efficacy of photodynamic therapy andtopical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006;31:634-7.

  63. Naveemuddin FA, Wong M, Yell J. Topicalphotodynamic therapy in disseminated superficial actinic porokeratosis.Clin Exp Dermatol 2002;27:703-6.

  64. Radakovik F, Blecha T, Schleyer V. Topical aminolaevulinic acid based photodynamic therapy as a treatment option for psoriasis?.Results of a randomiced, obsever-blinded study. Br J Dermatol2005;152:279-83.

  65. Schlever V, RadaKovic-Fijan S. Disappoin-ting results and low tolerability of photodynamic therapy with topical 5-aminolaevulinic acid in psoriasis. A randomized, double-blind phase I/II study. J Eur Acad Dermatol Venereol2006;20:823-8.

  66. Smits T, Kleinpening MM, van Erp PE. A placebo-controlled randomized study on the cli-nical effectiveness, inmmunohistochemicalchanges and protoporphyrin IX accumula-tion in fractionated 5-aminolaevulinic acid-photodynamic therapy in patients with pso-riasis. Br J Dermatol2006;155:429-36.

  67. Hauschild A, Lischner S. Treatment of acti-nic cheilitis using photodynamic therapywith metilaminolevulinate: report of treecases. Dermatol Surg2005;31:1344-8.

  68. Stender IM, Wolf HC. Photodynamic therapywith 5 aminolevulinic acid in the treatment ofactinic cheilitis. Br J Dermatol1996;135:454-6.

  69. Alexiades-Armenakas MR, Geronemus RG.Laser-mediated photodynamic therapy ofactinic cheilitis. J Drugs Dermatol 2004;3:548-51.

  70. Ehrig T, Cockerell C, Piacquadio D. Actinickeratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg2 006;32:1261-5.

  71. Angell-Petersen E, Sorensen R, Warloe T.Porphyrin formation in actinic keratosis and basal cell carcinoma alter topical application of methyl 5 aminolevulinate. J Invest dermatol2006;126:265-71.

  72. Tshen EH, Wong DS, Pariser DM. Photody-namic therapy using aminolaevulinic acid forpatients with non hyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up.Br J Dermatol 2006;155:1262-9.

  73. Gold MN, Nestor MS. Current treatments ofactinic keratosis. J Drugs Dermatol 2006;5:17-25.

  74. Dijkstra A. Terapia fotodinámica con luz ultravioleta y ácido aminolevulínico tópico para el tratamiento de queratosis actínicas, enfermedad de Bowen y carcinoma basocelular. J Eur Acad Dermatol Venereol 2002;3:16-20.

  75. Smith S, Piacquadio D. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003;2:629-35.

  76. Skiveren J, Haedersdal M, Philipsen PA. Morphine gel 0.3% does not relieve painduring topical photodynamic therapy: a randomzed double-blind, placebo=controled study. Acta Derm Venereol 2006;86:409-11.

  77. Sandberg C, Stenquist B, Rosdahl I. Important factors for pain during photodynamic therapy for actinic keratosis. Acta DermVenereol 2006;86:404-8.

  78. Taub AF. Photodynamic therapy in dermatology: history and horizons. J Drugs Dermatol 2004;3:S8-25.

  79. Fabbrocini G, Di Costanzo MP, Ricardo AM. Photodynamic therapy with topical delta-aminol aevulinic acid for the treatment of plantar warts. J Photochem Photobiol 2001;15;61:30-4.

  80. Chen HM, Chen CT, Yang H. Successful treatment of oral verrucous hyperplasia withtopical 5-aminolevulinic acid-mediated photodynamic therapy. Oral Oncol 2004;40:630-7.

  81. Herzinger T, Wienecke R, Weisenseel P.Photodynamic therapy of genital condylomata in men. Clin Exp Dermatol 2006;31:51-3.

  82. Gollnick SO, Owczarczak B, Maier P. Photodynamic therapy and anti-tumor immunity. Lasers Surg Med 2006;38:509-15.

  83. Shim CS. Photodynamic therapy in gastroenterology. Korean J Gastroenterol 2005;45:153-61.

  84. Endlicher E, Knuechel R, Hauser T. Fluores-cent endoscopy detection of low and highgrade dysplasia in Barrett’s oesophagus using systemic or local 5-aminolaevulinic acid sensitization. Gut 2001;48:314-9.

  85. Messmann H, Knuchel R, Baumler W. Fluorescent endoscopy detection of dysplasia in patients with Barrett´s esophagus, ulcerative colitis or adenomatous polyps after 5-amino-levulinic acid induced protoporphyrin IX sensitizacion. Gastrointest Endosc 1999;49:97-101.

  86. Grieb P. 5-Aminolevulinic acid (ALA) and its applications in surgery. Neurol NeurochirPol 2004;38:201-7.

  87. Hirshberg H, Sorensen DR. Repetitive photodynamic therapy of malignant brain tumor.J Environ Pathol Toxicol Oncol 2006;25:261-79.

  88. Stylli SS, Kaye AH, MacGregor L. Photodynamic therapy of high grade gliomalong termsurvival. J Clin Neurosci 2005;12:389-98.

  89. Arai T, Tani S, Isoshima A. Intraoperative photodynamic diagnosis for spinal ependymoma using 5-aminolevulinic acid: technical note. No Shinkei Geka 2006;34:811-7.

  90. McCaughan JS Jr, Williams TE Jr, Bethel BH. Photodynamic Therapy of Endobronchial Tumors. Lasers Surg Med 1986;6:336-45.

  91. Mathur PN, Edell E, Sutedja T, Vergnon J. Treatment of Early Stage Non-small Cell Lung Cancer. Chest 2003;123:176s-180s.

  92. Lam S Kostashuk EC, Coy EP. A randomized comparative study of the safety and efficacy of photodynamic therapy using porphyrin II combined with palliative radiotherapy versus palliative radiotherapy alone in patients with inoperable non small cell bronchogenic carcinoma.Photochem and photobiol 1987;46:893-7.

  93. Caviedes I, Badinez L, Cordiva A. Terapia fotodinámica en dos pacientes con metástasis endobronquiales de adenocarcinoma extrapulmonar. Rev Chil Enferm Respir 2003;19:38-42.

  94. Bonnette P, Heckly GB, Villette S, Fragola A. Intrauperative Photodynamic Therapy After Pleuropneumonectomy for Malignant Pleural Mesothelioma. Chest 2002;122:1866-7.

  95. OST D. Photodynamic therapy in lung cancer. Oncology 2000;14:379-91.

  96. Sickenberg M, Schmidth U. A preliminary study of photodynamic therapy using Verte-porfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000;117:327-36.

  97. TAP study group. Photodynamic therap neovascularization in age-related macular degeneration with Verteporfin. Arch Ophthalmol 1999;117:1329-45.

  98. Rodríguez-Coleman H, Spaide RF, Yannuzzi LA. Treatment of angiomatous lesions of the retina with photodynamic therapy. Retina 2002;22:228-32.

  99. D’Cruz AK, Robinson MH, Biel MA. mTHPC-mediated Photodynamic Therapy in Patients with Advanced, Incurable Head and Neck Cancer: A Multicenter Study of 128 Patients. Head Neck 2004;26:232-40.

  100. Biel MA. Photodynamic Therapy and the Treatment of Head and Neck Neoplasia. Laryngoscope 1998;108:1259-68.

  101. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 2005;4:283-93.

  102. Kriegmair M, Baumgartner R, Lumper W, Waidelich R, Hofstetter A. Early Clinical Experience with 5-aminolevulinic Acid forthe Photodynamic Therapy of Superficial Bladder Cancer. Br J Urol 1996;77:667-71.

  103. Martín NE, Hahn SM. Interstitial Photodynaic Therapy for Prostate Cancer: A Developing Modality. Photodiag Photodyn Therapy 2004;1:123-36.

  104. Selman SH, Keck RW. The Effect of Transurethral Light on the Canine Prostate After Sensitization with the Photosensitizer Tin(11) Etiopurpurin Dichloride: A Pilot Study. J Urol 1994;152:2129-213.




2020     |     www.medigraphic.com